Clinical trial · no report yet · Phase 2
NCT05642780
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- NCT05642780 ↗
- Active, not recruiting
- Klus Pharma Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Solid Tumor
- Interventions
- SKB264; Pembrolizumab
- Arms
- cohort A · Experimental
- cohort B · Experimental
- cohort C · Experimental
- cohort D · Experimental
- Cohort E · Experimental
- Enrollment
- 240 (estimated)
- Primary outcomes
- Dose limiting toxicity (DLT) and adverse events (AEs)
- Objective Response Rate (ORR)
- Prostate-specific antigen (PSA) response rate (Cohort D)
- Sponsor
- Klus Pharma Inc. with Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc., Clario
- Start
- Jan 17, 2023
- Primary completion
- Nov 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05642780 · updated Oct 14, 2025